

# AUSTRALIAN PRODUCT INFORMATION – LASIX (FUROSEMIDE (FRUSEMIDE)) TABLETS AND ORAL SOLUTION AND LASIX (FUROSEMIDE (FRUSEMIDE) SODIUM) INJECTIONS

## 1 NAME OF THE MEDICINE

For Oral Solution and Tablets: Furosemide (Frusemide)

For Injections: Furosemide (Frusemide) sodium

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Lasix M Tablets contain 20 mg furosemide (frusemide).

Lasix Tablets contain 40 mg furosemide (frusemide).

Lasix Oral Solution contains 10 mg/mL furosemide (frusemide).

Lasix 20 mg/2 mL injection: each 2 mL contains 20 mg furosemide (frusemide) as furosemide (frusemide) sodium. Contains 0.16 mmol/mL of sodium.

Lasix 40 mg/4 mL injection: each 4 mL contains 40 mg furosemide (frusemide) as furosemide (frusemide) sodium. Contains 0.16 mmol/mL of sodium.

### Excipients with known effect

Lasix 20 mg and 40 mg tablets contain sugars as lactose.

Lasix Oral Solution contains benzoates, sorbitol and alcohol.

For the full list of excipients, see Section 6.1 List of excipients.

## 3 PHARMACEUTICAL FORM

Lasix M Tablets 20 mg tablets are white, round flat-faced tablets with bevelled edge debossed with “DLF” on one side and plain on the other face.

Lasix 40 mg tablets are yellow, round, flat-faced tablets with bevelled edge debossed with “LASIX ” above the score line and “40” below the score line on one side, and the Hoechst logo on the other side.

Lasix Oral Solution is a clear yellow liquid.

Lasix Injections are clear colourless solutions, practically free of visible particles.

## **4 CLINICAL PARTICULARS**

### **4.1 THERAPEUTIC INDICATIONS**

#### **Oedema**

Lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. Lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.

Lasix Injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, Lasix is indicated by the intravenous route. Parenteral use should be replaced with oral Lasix as soon as practical.

#### **Hypertension**

Oral Lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with Lasix alone.

### **4.2 DOSE AND METHOD OF ADMINISTRATION**

#### **Oral Administration**

##### ***Oedema***

Therapy should be individualised according to patient's response. This therapy should be titrated to gain maximal therapeutic response with the minimum dose possible to maintain that diuretic response.

##### ***Adults***

The usual initial daily dose is 20 to 80 mg given as a single dose. If the diuretic response to a single dose of 20 to 80 mg is not satisfactory, increase this dose by increments of 20 to 40 mg, not sooner than 6 to 8 hours after the previous dose, until the desired diuretic effect is obtained. This individually determined dose should be given once or twice (e.g. at 8 am and 2 pm) daily. The dose of Lasix may be carefully titrated up to 400 mg/day (except in advanced renal failure) in those patients with severe clinical oedematous states. The mobilisation of oedema may be most efficiently and safely accomplished by giving Lasix on 2 to 4 consecutive days each week.

When doses exceeding 80 mg/day are given for prolonged periods, careful clinical laboratory observations are particularly advisable.

### *Infants and Children*

The usual initial dose of oral Lasix for infants and children is 2 mg/kg body weight given as a single dose. If the diuretic response is not satisfactory, the dose may be increased by 1 to 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses of greater than 6 mg/kg body weight are not recommended.

For maintenance therapy in infants and children, the dose should be adjusted to the minimum effective level.

### **Hypertension**

Therapy should be individualised according to the patient's response. This therapy should be titrated to gain maximal therapeutic response with the minimum dose possible to maintain that therapeutic response.

### *Adults*

The usual initial daily dose of Lasix for hypertension is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.

Changes in blood pressure must be carefully monitored when Lasix is used with other antihypertensive drugs, especially during initial therapy.

To prevent an excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50% when Lasix is added to the regimen. As the blood pressure falls under the potentiating effect of Lasix, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.

### **Parenteral Administration**

#### *Adults*

Parenteral therapy with Lasix injection should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical. To achieve optimum efficacy and suppress counter-regulation, a continuous furosemide (frusemide) infusion is generally preferred to repeat bolus injections.

Intramuscular administration must be restricted to exceptional cases where neither oral nor intravenous administration are feasible. It must be noted that intramuscular injection is not suitable for the treatment of acute conditions such as pulmonary oedema.

#### *Oedema*

The usual initial dose of Lasix is 20 to 40 mg given as a single dose, injected intramuscularly or intravenously. The intravenous dose should be given slowly (see Section 4.4 Special warnings and precautions for use). Ordinarily a prompt diuresis ensues. If needed, another dose may be administered in the same manner 2 hours later, or the dose may be increased. The dose may be raised by 20 mg and given not sooner than 2 hours after the previous dose,

until the desired diuretic effect has been obtained. This individually determined single dose should then be given once or twice daily.

Therapy should be individualised according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Close medical supervision is necessary. If the physician elects to use high dose parenteral therapy, add the Lasix to either Sodium Chloride Injection or Lactated Ringer's Injection, and administer as a controlled intravenous infusion at a rate not greater than 4 mg/min. Lasix Injection is a buffered alkaline solution.

#### *Acute Pulmonary Oedema*

The usual initial dose of Lasix is 40 mg injected slowly intravenously (see Section 4.4 Special warnings and precautions for use). If a satisfactory response does not occur within 1 hour, the dose may be increased to 80 mg injected slowly intravenously. If necessary, additional therapy (e.g. digitalis, oxygen) may be administered concomitantly.

#### *Cerebral Oedema*

The following procedure is recommended, pending further experience:

Intravenous injection of 20 to 40 mg three times daily. A more uniform diuretic action is obtained if the same doses are infused. The rate of infusion must be determined individually in accordance with the diuretic action and the neurological findings.

#### **Infants and Children**

Parenteral therapy should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical.

The recommended dose of Lasix Injection (intravenously or intramuscularly) in infants and children is 1 mg/kg body weight and should be given slowly under close medical supervision. If the diuretic response to the initial dose is not satisfactory, dosage may be increased by 1 mg/kg not sooner than 2 hours after the previous dose, until the desired effect has been obtained. Doses of greater than 6 mg/kg body weight are not recommended.

Lasix Injection should be inspected visually for particulate matter and discolouration before administration. Do not use if solution is discoloured.

Although the chemical stability of diluted Lasix Injection has been demonstrated for storage at 25°C for 24 hours, the diluted solution should be used as soon as practicable to reduce risk of microbiological hazard. If storage is necessary, hold the diluted solution at 2 - 8°C for not more than 24 hours.

### **4.3 CONTRAINDICATIONS**

Known hypersensitivity to furosemide (frusemide) or sulfonamides or any of the inactive ingredients (see Section 6.1 List of excipients description). Patients allergic to sulfonamides (e.g. sulfonamide antibiotics or sulfonylureas) may show cross-sensitivity to Lasix.

Complete renal shutdown; impaired renal function or anuria. If increasing azotaemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide (frusemide).

Severe hypokalaemia, (see Section 4.8 Adverse effects (undesirable effects), hyponatraemia, hypovolaemia, dehydration or hypotension must be regarded as contraindications until serum electrolytes, fluid balance and blood pressure have been restored to normal levels.

In hepatic coma or precoma and conditions producing electrolyte depletion, furosemide (frusemide) therapy should not be instituted until the underlying conditions have been corrected or ameliorated.

In breast-feeding or pregnant women.

Do not administer furosemide (frusemide) to newborns presenting jaundice or to infants with conditions which might induce hyperbilirubinaemia or kernicterus (e.g. Rhesus incompatibility, familial non-haemolytic jaundice etc.) because of furosemide's (frusemide's) 'in vitro' potential to displace bilirubin from albumin.

Lasix 250 mg injection must not be used as a bolus injection. It must only be infused using volume or rate-controlled infusion pumps to reduce the risk of accidental overdose.

#### **4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

##### **Identified precautions**

Excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse and with the possibility of vascular thrombosis and embolism, particularly in elderly patients.

Particularly careful monitoring is required in patients with gout, patients with partial obstruction of urinary outflow, in patients with hypotension or who are at particular risk from a pronounced fall in blood pressure (e.g. patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain), in patients with latent or manifest diabetes mellitus, in patients with hepatorenal syndrome or in patients with hypoproteinaemia (e.g. associated with nephrotic syndrome). Dose titration, especially in this latter case, is required.

Cases of reversible or irreversible tinnitus or hearing impairment have been reported. Usually, reports indicate that Lasix ototoxicity is associated with rapid injection or infusion, severe renal impairment, hypoproteinaemia, doses exceeding several times the usual recommended dose, or concomitant therapy with aminoglycoside antibiotics, etacrynic acid, or other ototoxic drugs. In patients with hypoproteinaemia, e.g. associated with nephrotic syndrome, the effect of Lasix may be weakened, and its ototoxicity potentiated. Cautious dose titration is required. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults with normal renal function, an infusion rate not exceeding 4 mg Lasix per minute must be used; for adults with impaired renal function [creatinine > 5 mg/dL], an infusion rate of no greater than 2.5 mg per minute must be used).

Caution should be exercised when administering curare or its derivatives to patients undergoing furosemide (frusemide) therapy. It is also advisable to discontinue furosemide (frusemide) for one week prior to any elective surgery.

Caution should be exercised and the risks and benefits of combining risperidone with Lasix or other potent diuretics should be considered prior to the decision to treat. In the risperidone placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide (frusemide) plus risperidone (7.3%; mean age 89 years, range 75 to 97) compared to treatment with risperidone alone (3.1%; mean age 84 years, range 70 to 96) or furosemide (frusemide) alone (4.1%; mean age 80 years, range 67 to 90). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low doses) was not associated with similar mortality findings. No pathophysiological mechanism has been identified to explain this finding and no consistent pattern for cause of death was observed. Nevertheless, caution is advised. Irrespective of treatment, dehydration was an overall risk factor for mortality and should, therefore, be carefully avoided in elderly patients with dementia.

Rigid sodium restriction is conducive to both hyponatraemia and hypokalaemia, thus strict restriction of sodium intake is not advisable in patients receiving furosemide (frusemide).

Excessive loss of potassium in patients receiving cardiac glycosides may precipitate digitalis toxicity.

During long-term therapy, a high potassium diet is recommended. Potassium supplements may be required, especially when high doses are used for prolonged periods. Particular caution with potassium is necessary when the patient is on digitalis glycosides, potassium depleting steroids or in the case of infants and children. Potassium supplementation, diminution in dose, or discontinuation of furosemide (frusemide) therapy may be required.

As with many other drugs, patients should be observed regularly for the possible occurrence of blood dyscrasias, liver damage, or other idiosyncratic reactions.

The possibility exists of exacerbation or activation of systemic lupus erythematosus.

### **Excipient Warning**

Ethanol (Alcohol) – Lasix Oral Solution contains 12.7% v/v ethanol (alcohol). The safety of ethanol at a concentration of 12.7% v/v in a medicine intended for use in children has not been established. This should be taken into consideration when deciding whether to prescribe Lasix Oral Solution in this age group.

The ethanol content of this formulation (0.5 g per 5 ml dose) is harmful to those suffering from alcoholism. This should also be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.

The sorbitol present in the vehicle may cause diarrhoea (especially in children) when higher doses of Lasix Oral Solution are given.

When Lasix is administered parenterally, a maximum injection rate of 4 mg/minute should be used to minimise the risk of ototoxicity.

Intramuscular administration of Lasix must be limited to exceptional cases where neither oral nor intravenous administration are feasible. Intramuscular administration is not suitable for acute conditions such as pulmonary oedema.

### **Use in hepatic impairment**

In patients with hepatic cirrhosis and ascites, initiation of therapy with Lasix is best carried out in hospital. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma, therefore, strict observation is necessary during the period of diuresis.

### **Use in renal impairment**

Furosemide (Frusemide) should be used with care, especially in the initial stages, in patients with impairment of micturition (e.g. prostatic hypertrophy). Urinary outflow must be secured. In patients with a partial obstruction of urinary outflow (e.g. in patients with bladder-emptying disorders, prostatic hyperplasia or narrowing of the urethra), increased production of urine may provoke or aggravate complaints. Thus, these patients require careful monitoring.

Patients who were at high risk for radiocontrast nephropathy treated with furosemide (frusemide) experienced a higher incidence of deterioration in renal function after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrast.

### **Use in the elderly**

See “Identified precautions” and Section 4.8 Adverse effects (undesirable effects) “Metabolism and Nutritional Disorders”, “Renal and Urinary Disorders” and “Vascular Disorders”

### **Paediatric use**

In premature infants, there is the possible development of nephrocalcinosis/nephrolithiasis and therefore renal function must be monitored and renal ultrasonography performed. In premature infants, furosemide (frusemide) administered during the first weeks of life may increase the risk of persistence of Botallo’s duct.

In children, urge to defecate, complaints of abdominal pain and cramping have been reported after IV furosemide (frusemide). An association of these symptoms with a low serum calcium and/or a low calcium/protein ratio is possible.

Renal calcifications (from barely visible on X-ray to staghorn) have occurred in some severely premature infants treated with intravenous Lasix for oedema due to patent ductus arteriosus and hyaline membrane disease. The concurrent use of chlorothiazides has been reported to decrease hypercalciuria and to dissolve some calculi.

## **Effects on laboratory tests**

As with any effective diuretic, electrolyte depletion may occur during therapy, especially in patients receiving higher doses and a restricted salt intake. All patients receiving Lasix therapy should be observed for signs of fluid or electrolyte imbalance; namely hyponatraemia, hypochloraemic alkalosis, and hypokalaemia. Periodic determinations of serum electrolytes to detect a possible imbalance should be performed at appropriate intervals, as well as creatinine, blood urea and CO<sub>2</sub> content determinations. This is particularly important when the patient is at high risk of developing electrolyte imbalances (eg. receiving parenteral fluids) or in case of significant additional fluid loss such as vomiting diarrhoea and intense sweating. Warning signs of an imbalance, irrespective of cause include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, and gastrointestinal disturbances such as nausea and vomiting. Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Lasix.

Periodic checks on urine and blood glucose should be made in diabetics and even those suspected of latent diabetes when receiving Lasix. Increases in blood glucose and alterations in glucose tolerance tests with abnormalities of the fasting and 2-hour post prandial sugar have been observed, and rare cases of precipitation of diabetes mellitus have been reported.

Lasix may lower calcium levels, and rare cases of tetany have been reported. Accordingly, periodic serum calcium levels should be obtained.

Reversible elevations of blood urea may be seen. These have been observed in association with dehydration, which should be avoided, particularly in patients with renal insufficiency.

Furosemide (Frusemide) increases cholesterol and triglycerides short-term. It is not clear whether this effect persists long-term, however, the current evidence does not indicate this.

Asymptomatic hyperuricaemia can occur and rarely, gout may be precipitated.

## **4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

### **Interactions with Food**

Whether and to what extent the absorption of Lasix is affected by taking it with food seems to depend on the pharmaceutical formulation of Lasix. It is recommended that oral formulations of Lasix be taken on an empty stomach.

### **Combinations that are not recommended**

#### ***Antibiotics***

Lasix may increase the ototoxic and nephrotoxic potential of certain antibiotics (e.g. aminoglycosides and certain cephalosporins (e.g. cephaloridine)) and other ototoxic drugs, especially in the presence of impaired renal function, therefore the simultaneous administration of these drugs is not advisable.



### ***Anticonvulsants***

Anticonvulsants may decrease the response to furosemide (frusemide). In isolated cases intravenous administration of furosemide (frusemide) within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure and tachycardia. Use of furosemide (frusemide) concomitantly with chloral hydrate is, therefore, not recommended.

### **Combinations that require precautions**

#### ***Etacrynic acid or cisplatin***

Lasix should not be used concomitantly with etacrynic acid or cisplatin because of the possibility of ototoxicity. In addition, nephrotoxicity of cisplatin may be enhanced if Lasix is not given in low doses (e.g. 40 mg in patients with normal renal function) and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.

#### ***Lithium salts***

Furosemide (Frusemide) decreases the excretion of lithium salts and may cause increased serum lithium levels, resulting in increased risk of lithium toxicity, including increased risk of cardiotoxic and neurotoxic effects of lithium. Therefore, it is recommended that lithium levels are carefully monitored in patients receiving this combination.

#### ***Sucralfate***

Oral furosemide (frusemide) and sucralfate must not be taken within two hours of each other because sucralfate decreases the absorption of furosemide (frusemide) from the intestine and hence, reduces its effect.

#### ***Antihypertensives***

The action of other antihypertensive drugs may be potentiated by Lasix, especially in combination with ACE inhibitors. The administration of ACE inhibitors to patients pretreated with furosemide (frusemide) may lead to a deterioration in renal function including renal failure, or may result in severe hypotension especially when an angiotensin converting enzyme inhibitor (ACE inhibitor) or angiotensin II receptor antagonist is given for the first time or for the first time in an increased dose. Consideration must be given to interrupting the administration of Lasix temporarily or at least reducing the dose of Lasix for 3 days before starting treatment with or increasing the dose of an ACE inhibitor or angiotensin II receptor antagonist.

#### ***Risperidone***

Caution should be exercised and the risks and benefits of treating a patient on risperidone with Lasix or other potent diuretics should be considered prior to the decision to use. See Section 4.4 Special warnings and precautions for use, regarding increased mortality in elderly patients with dementia concomitantly receiving risperidone.

### ***Levothyroxine sodium***

High doses of furosemide (frusemide) may inhibit binding of thyroid hormones to carrier proteins when administered with levothyroxine sodium, and thereby lead to an initial transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. It is recommended that thyroid hormones be monitored.

### **Other Combination to Consider**

#### ***Drugs inducing QT interval prolongation***

The effects of digitalis preparations and drugs inducing QT interval prolongation syndrome may be potentiated by changes in electrolyte concentrations (e.g. hypokalaemia, hypomagnesaemia) due to furosemide (frusemide). When a cardiac glycoside is administered concurrently, it should be remembered that potassium or magnesium deficiency increases the sensitivity of the myocardium to digitalis, and may increase the toxicity of drugs which induce QT interval prolongation syndrome. When a glucocorticoid is administered during diuretic treatment, the potassium-lowering effect of the steroid should be borne in mind (see Section 4.4 Special warnings and precautions for use). Carbenoxolone, corticosteroids, prolonged use of laxatives or ingestion of liquorice in large amounts may also predispose a patient to hypokalaemia.

#### ***Salicylates***

Patients receiving high doses of salicylates, as in rheumatic disease, in conjunction with Lasix may experience salicylate toxicity at lower doses because of competitive renal excretory sites.

#### ***Neuromuscular blockers***

Interactions between furosemide (frusemide) and neuromuscular blocking agents have been reported. These appear to be dependent on the dose of furosemide (frusemide) and the neuromuscular blocking agent involved. Low doses of furosemide (frusemide) (0.1 - 10 µg/kg) enhance the neuromuscular blockade of tubocurarine and succinylcholine. High doses (1 - 5 mg/kg) of furosemide (frusemide) have a tendency to antagonise the skeletal muscle relaxing effect of tubocurarine but may potentiate the action of succinylcholine. The clinical relevance of these findings is uncertain.

#### ***Amphotericin B (amphotericin)***

The combination of furosemide (frusemide) and amphotericin B (amphotericin) may result in an excessive loss of potassium.

#### ***Noradrenaline (norepinephrine)***

Lasix may decrease arterial responsiveness to noradrenaline (norepinephrine). This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

If antihypertensive agents, diuretics or other drugs with blood-pressure lowering potential are given concomitantly with Lasix, a more pronounced fall in blood pressure must be anticipated.

### ***Non-steroidal anti-inflammatory drugs***

Non-steroidal anti-inflammatory drugs including acetylsalicylic acid may reduce the natriuretic and antihypertensive effects of Lasix in some patients by inhibiting prostaglandin synthesis. In patients with dehydration or pre-existing hypovolaemia, non-steroidal anti-inflammatory drugs may cause acute renal failure. Salicylate toxicity may be increased by furosemide (frusemide).

### ***Drugs eliminated by renal tubular secretion***

Phenytoin, methotrexate, probenecid and other drugs which, like furosemide (frusemide) undergo significant renal tubular secretion may reduce the effect of furosemide (frusemide). Conversely furosemide (frusemide) may decrease renal elimination of these drugs. In the case of high dose treatment (in particular of both furosemide (frusemide) and the other drugs), this may lead to an increased risk of adverse effects due to furosemide (frusemide) or the concomitant medication.

### ***Theophylline***

IV furosemide (frusemide) was shown to increase the steady state concentration of theophylline by 20% in a small number of asthmatic patients; hence it is appropriate to measure serum theophylline levels when both drugs are given together.

### ***Muscle relaxants***

The effects of curare-type muscle relaxants or of theophylline may be increased.

### ***Antidiabetic agents and adrenaline (epinephrine)***

It should be borne in mind that the effect of antidiabetics or of pressor amines (e.g. adrenaline (epinephrine), noradrenaline (norepinephrine)) may be attenuated by furosemide (frusemide) (see Section 4.4 Special warnings and precautions for use).

### ***Cephalosporins***

Impairment of renal function may develop in patients receiving concurrent treatment with furosemide (frusemide) and high doses of certain cephalosporins. The harmful effects of nephrotoxic drugs on the kidney may be increased.

### ***Ciclosporin***

Concomitant use of ciclosporin A and furosemide (frusemide) is associated with increased risk of gouty arthritis secondary to furosemide (frusemide)-induced hyperuricemia and ciclosporin impairment of renal urate excretion.

## **4.6 FERTILITY, PREGNANCY AND LACTATION**

### **Effects on fertility**

No data available

### **Use in pregnancy – Pregnancy Category C**

Lasix must not be given during pregnancy unless there are compelling medical reasons. Treatment during pregnancy requires monitoring of foetal growth.

Thiazides, related diuretics and loop diuretics enter the foetal circulation and may cause electrolyte disturbances. Neonatal thrombocytopaenia has been reported with thiazides and related diuretics. Loop diuretics, like furosemide (frusemide) and bumetanide, are probably also associated with this risk. During the latter part of pregnancy, products of this type should only be given on sound indications, and then in the lowest effective dose. In pregnancy, furosemide (frusemide) must only be used in patients with a marked reduction in glomerular filtration.

### **Use in lactation.**

Furosemide (Frusemide) passes into the breast milk and inhibits lactation. Women must not breast feed if being treated with furosemide (frusemide).

## **4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

Some adverse effects (e.g. an undesirable pronounced fall in blood pressure) may impair the patient's ability to concentrate and react and therefore constitute a risk in situations where these abilities are of special importance (e.g. operating a vehicle or machinery).

## **4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)**

Whenever adverse reactions are moderate or severe, furosemide (frusemide) dose should be reduced or therapy withdrawn.

### **Metabolism and Nutritional Disorders**

As with other diuretics, electrolytes and water balance may be disturbed during therapy with furosemide (frusemide), especially in patients receiving high doses for a prolonged period. The serum potassium concentration may decrease, especially at the commencement of treatment (owing to the earlier onset of action of furosemide (frusemide)).

Excessive diuresis may give rise, especially in elderly patients and children, to circulatory disturbances such as headache, dizziness, dry mouth or visual impairment, as symptoms of hypovolaemia. In extreme cases, hypovolaemia and dehydration may lead to hypotension, circulatory collapse and, in elderly patients in particular, thrombophilia. However, with individualised dosage, acute haemodynamic reactions are generally not to be expected, although diuresis sets in rapidly.

All saluretics may cause hypokalaemia, mainly in cases of low potassium diet, vomiting or chronic diarrhoea.

Factors such as underlying diseases (liver cirrhosis, cardiac failure), concomitant medication (see Section 4.5 Interactions with other medicines and other forms of interactions) or nutritional inadequacies (excessive restriction of salt intake), may lead to sodium (hyponatremia), chloride (hypochloremia), or other electrolyte or fluid deficiencies which may produce a fall in orthostatic blood pressure, calf muscle spasms, anorexia, weakness, dizziness, drowsiness, apathy, vomiting and confusion.

Furosemide (Frusemide) may lower the serum calcium level (hypocalcemia) which may trigger a state of increased neuromuscular irritability. Furosemide (Frusemide) may cause a rise in serum cholesterol and triglyceride.

Hypomagnesaemia and, in rare cases, tetany or cardiac arrhythmias have been observed as a consequence of increased renal magnesium loss.

Treatment with Lasix may lead to transitory increases in urine volume, blood creatinine and urea levels. Serum levels of uric acid (hyperuricaemia) may increase and attacks of gout may occur.

Pre-existing metabolic alkalosis (e.g. due to decompensated liver cirrhosis) may be aggravated during furosemide (frusemide) treatment. Metabolic alkalosis has been reported with furosemide (frusemide) use.

Treatment with furosemide (frusemide) has occasionally caused reduced glucose tolerance and deterioration in cases of manifest diabetes, or made latent diabetes manifest.

Pseudo-Bartter syndrome in the context of misuse and/or long-term use of furosemide (frusemide) has been reported.

Very common: electrolyte disturbances (including symptomatic), dehydration and hypovolaemia especially in elderly patients, increased blood creatinine, increased blood triglycerides

Common: hyponatremia, hypochloremia, hypokalaemia, blood cholesterol increased, blood uric acid increased and attacks of gout, urine volume increased

Uncommon: impaired glucose tolerance. Latent diabetes mellitus may manifest

### **Gastrointestinal Disorders and Hepato-biliary Disorders**

Reactions with normal doses are uncommon with Lasix. They include anorexia, oral and gastric irritation, nausea, vomiting, cramping, diarrhoea and constipation.

In isolated cases, acute pancreatitis and increases in transaminases have been observed. Additionally, cholestasis and jaundice have been reported. Furosemide (Frusemide) may increase the bile flow and distend the biliary tree which is already obstructed.

## **Central Nervous System Disorders**

Reactions such as dizziness, vertigo, paraesthesia, headache and blurred vision occasionally accompany Lasix induced diuresis.

## **Ear and Labyrinth Disorders**

Reversible hearing impairment and tinnitus and rarely, permanent tinnitus and impairment of hearing have been observed, especially in patients with markedly reduced renal function or hypoproteinaemia (e.g. in nephrotic syndrome). This occurs particularly when the recommended rate of injection or infusion of 4 mg per minute (normal renal function) or 2.5 mg per minute (impaired renal function) is exceeded, or in patients who are also receiving drugs known to be ototoxic.

Cases of deafness, sometimes irreversible have been reported after oral or IV administration of furosemide (frusemide).

## **Skin and Subcutaneous Tissue Disorders**

Uncommon allergic reactions include dermatitis, dermatitis bullous, rashes, urticaria, pruritus, photosensitivity reactions, pemphigoid, erythema multiforme, purpura and exfoliative dermatitis. Itching may occur and rare cases of necrotising angitis, Steven-Johnson syndrome, toxic epidermal necrolysis. AGEP (acute generalized exanthematous pustulosis), lichenoid reactions and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) has been reported with furosemide (frusemide) use.

## **Blood and the Lymphatic System Disorders**

Common: haemoconcentration

Uncommon: thrombocytopenia

The following rare adverse reactions have been reported: eosinophilia, thrombophlebitis, haemolytic or aplastic anaemia, leukopaenia and agranulocytosis.

## **Congenital and familial/genetic disorders**

The persistence of patent ductus arteriosus when furosemide (frusemide) has been administered to a premature infant during the first weeks of life has been reported.

## **Renal and Urinary Disorders**

Excessive diuresis and dehydration could cause transient elevation of creatinine and BUN and reduction of GFR. Rare cases of tubulointerstitial nephritis have been reported. In elderly men with prostatic hypertrophy, acute urinary retention with overflow incontinence may occur. Symptoms of existing conditions of obstructed micturition, such as ureterostenosis or hydronephrosis, may be triggered or aggravated by pronounced diuresis. Interstitial nephritis has also been reported with furosemide (frusemide) use. In premature infants, calcium salts may be deposited in the renal tissue (nephrocalcinosis/ nephrolithiasis). In patients with a partial obstruction of urinary outflow, acute retention of urine may occur.

Increases in sodium and/or chloride urine levels, and renal failure has been reported with furosemide (frusemide) use.

### **Vascular Disorders**

Very common (especially for intravenous infusion), orthostatic hypotension may occur and may be aggravated by alcohol, narcotics and barbiturates. Due to the possibility of side effects such as hypotension, patients' ability to drive or operate machinery may be impaired, especially at the commencement of therapy. Ischaemic complications have also been reported in elderly patients. A tendency for thromboses has been reported. If furosemide (frusemide) is administered to premature infants during the first weeks of life, it may increase the risk of persistence of patent ductus arteriosus.

Rare: vasculitis

Cases of thrombosis have been reported.

### **Immune System Disorders**

Severe anaphylactic or anaphylactoid reactions (e.g. with shock) is rare, but is acutely life-threatening if it does occur.

Cases of exacerbation or activation of systemic lupus erythematosus have been reported.

### **Nervous System Disorders**

Common: hepatic encephalopathy in patients with hepatocellular insufficiency

Rare: paraesthesia

Headache, dizziness, fainting or loss of consciousness have been reported.

### **Musculoskeletal and connective tissue disorders**

Cases of rhabdomyolysis have been reported, often in the context of severe hypokalaemia (see Section 4.3 Contraindications).

### **General Disorders and Administration Site Conditions**

Rarely, fever may occur. Following intramuscular injection, local reactions such as pain may occur. Restlessness has also been reported.

### **Reporting suspected adverse effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## 4.9 OVERDOSE

The clinical picture in acute or chronic overdose depends primarily on the extent and consequences of electrolyte and fluid loss; e.g. dehydration, blood volume reduction, hypotension, electrolyte imbalance, cardiac arrhythmias (including A-V block and ventricular fibrillation), hypokalaemia and hypochloraemic alkalosis, and extensions of its diuretic action. Symptoms of these disturbances include severe hypotension (progressing to shock), acute renal failure, thrombosis, delirious states, flaccid paralysis, apathy and confusion.

The acute toxicity of Lasix has been determined in mice, rats and dogs. In all three, the oral LD50 exceeded 1000 mg/kg body weight, while the intravenous LD50 ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats. The concentration of Lasix in biological fluids associated with toxicity or death is not known.

No specific antidote to Lasix is known. If ingestion has only just taken place, attempts may be made to limit further systemic absorption of the active ingredient by measures such as activated charcoal.

Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). Haemodialysis does not accelerate furosemide (frusemide) elimination.

For information of the management of overdose, contact the Poison information Centre on 131126 (Australia)

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 PHARMACODYNAMIC PROPERTIES

#### Mechanism of action

Lasix is a potent diuretic. It inhibits sodium and chloride absorption in the ascending limb of Henle's loop and in both the proximal and distal tubules. The high degree of efficacy is due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase or aldosterone.

Furosemide (Frusemide) may promote diuresis in cases which have previously proved resistant to other diuretics.

Furosemide (frusemide) has no significant pharmacological effects other than on renal function.

#### Clinical trials

No data available.



## 5.2 PHARMACOKINETIC PROPERTIES

### Absorption

Furosemide (frusemide) is rapidly absorbed from the GIT. Absorption rates in healthy subjects have been reported from 60 - 69% and from 43 - 46% in patients with end stage renal failure.

The onset of diuresis following oral administration is within 1 hour. The peak effect occurs within the first or second hour. The duration of diuretic effect is 6 to 8 hours.

The onset of diuresis following intravenous administration is within 5 minutes and somewhat later after intramuscular administration. The peak effect occurs within the first half hour. The duration of diuretic effect is approximately 2 hours.

In fasted normal men, the mean bioavailability of furosemide (frusemide) from Lasix Tablets and Lasix Oral Solution is 64% and 60% respectively of that from an intravenous injection of the drug. Although furosemide (frusemide) is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose, but times-to-peak do not differ among doses.

### Distribution

Furosemide (Frusemide) is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 µg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations.

### Metabolism

Recent evidence suggests that furosemide (frusemide) glucuronide is the only, or at least the major, bio-transformation product of furosemide (frusemide) in man.

### Excretion

In patients with normal renal function, approximately 80% of an intravenous or intramuscular dose is excreted in the urine within 24 hours. Urinary excretion is accomplished both by glomerular filtration and proximal tubular secretion, which accounts for roughly 66% of the ingested dose, the remainder being excreted in the faeces. A small fraction is metabolised by cleavage of the side chain.

Significantly more furosemide (frusemide) is excreted in urine following the IV injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine.

Furosemide (Frusemide) has a biphasic half-life in the plasma with  $t_{1/2}$  ranging up to 100 minutes;  $t_{1/2}$  is prolonged by renal and hepatic insufficiency and in newborn infants.

### **5.3 PRECLINICAL SAFETY DATA**

#### **Genotoxicity**

No data available.

#### **Carcinogenicity**

No data available.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 LIST OF EXCIPIENTS**

Lasix M Tablets 20 mg inactive ingredients are lactose monohydrate, maize starch, colloidal anhydrous silica, purified talc and magnesium stearate.

Lasix Tablets 40 mg inactive ingredients are lactose monohydrate, maize starch, colloidal anhydrous silica, purified talc, magnesium stearate, sunset yellow FCF and quinoline yellow aluminium lake.

Lasix Oral Solution inactive ingredients are sorbitol solution (70 per cent) (non-crystallising), glycerol, sodium hydroxide, methyl hydroxybenzoate, propyl hydroxybenzoate, ethanol, quinoline yellow, sunset yellow FCF, Trusil Orange Flavour 10814413 (ARTG PI No: 106046), purified water.

Lasix 20 mg/2 mL and 40 mg/4 mL injections inactive ingredients are sodium chloride, sodium hydroxide and water for injections.

### **6.2 INCOMPATIBILITIES**

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

### **6.3 SHELF LIFE**

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

### **6.4 SPECIAL PRECAUTIONS FOR STORAGE**

#### **Tablets and oral solution**

Store below 25°C. Protect from light. Use within 8 weeks of opening.

## Injections

Store below 25°C. Protect from light. Occasionally crystal deposits may be seen when ampoules are stored at low temperatures which dissolve on warming up to 40°C. Use within 8 weeks of opening.

### 6.5 NATURE AND CONTENTS OF CONTAINER

Lasix M Tablets 20 mg: 50s in HDPE bottles with a polypropylene closure.

Lasix Tablets 40 mg: 100s in HDPE bottles with a polypropylene closure.

Lasix Oral Solution: 30 mL glass Type III coloured bottles with a child resistant polypropylene closure.

Lasix Injections: amber Type I glass ampoules in packs of 5.

### 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.


### 6.7 PHYSICOCHEMICAL PROPERTIES

Furosemide (frusemide) and furosemide (frusemide) sodium are anthranilic acid derivatives.


Chemically, they are 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid and sodium; 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid.

Furosemide (frusemide) and furosemide (frusemide) sodium are white to off-white odourless crystalline powders. They are practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids.

#### 6.7.1 Chemical structure



furosemide



furosemide sodium

#### 6.7.2 CAS number

54-31-9 furosemide

41733-55-5 furosemide sodium

## 7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (Schedule 4)

## 8 SPONSOR

sanofi-aventis australia Pty Ltd  
12-24 Talavera Road  
Macquarie Park NSW 2113  
Australia

Toll Free Number (medical information): 1800 818 806

Email: medinfo.australia@sanofi.com

## 9 DATE OF FIRST APPROVAL

1 August 1991

## 10 DATE OF REVISION

31 January 2022

### Summary table of changes

Section Changed	Summary of new information
Title	Minor change to wording of title
1	Change in wording from 'ampoules' to 'injections'
2	Removal of reference to Lasix Oral Solution (refrigerated formulation) Minor change to wording and addition of information for 'excipients with known effect'
3	Minor change to wording Addition of reference to Oral Solution and Injection
6.1	Removal of reference to Lasix Oral Solution (refrigerated formulation) Minor change to wording
6.4	Addition of storage information for Lasix Oral Solution, tablets and injections
6.5	Removal of reference to availability of two Lasix Oral Solution Formulations Minor change to wording and addition of container and closure materials
6.7	Relocation of wording from sections 2 and 3 Minor change to wording and additional information for furosemide (frusemide) sodium